Acuitas Therapeutics Inc. and CureVac NV have settled their clash over who controls patents central to a blockbuster Covid-19 shot, according to filings in Virginia federal court.
Vancouver-based Acuitas sued CureVac, its German collaborator, last November seeking to have four Acuitas scientists—including a co-founder—added as inventors to four of 10 patents that CureVac alleges are infringed by
- Acuitas and Curevac also filed a notice of settlement Thursday in another case, in which ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.